ORCID Profile
0009-0000-9335-0744
Current Organisation
elmTEK PTY LTD
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: IEEE
Date: 2006
Publisher: IEEE
Date: 08-2006
Publisher: Cambridge University Press (CUP)
Date: 31-10-2023
DOI: 10.1017/AER.2023.94
Publisher: IEEE
Publisher: IEEE
Publisher: No publisher found
Publisher: IEEE
Publisher: IEEE
Date: 2006
Publisher: IEEE
Publisher: Elsevier BV
Date: 09-2016
DOI: 10.1016/J.IJROBP.2016.04.024
Abstract: To report the first comprehensive investigation of patient-reported cosmesis and breast-related quality of life (QOL) outcomes comparing patients randomized to risk-adapted single-dose intraoperative radiation therapy (TARGIT-IORT) versus external beam radiation therapy (EBRT) on the TARGIT-A trial. Longitudinal cosmesis and QOL data were collected from a subset of TARGIT-A participants who received TARGIT-IORT as a separate procedure (postpathology). Patients completed a cosmetic assessment before radiation therapy and annually thereafter for at least 5 years. Patients also completed the combined European Organization for Research and Treatment of Cancer (EORTC) core questionnaire and Breast-Specific Module in addition to the Body Image after Breast Cancer Questionnaire at baseline and annually thereafter. The combined EORTC questionnaires were also collected 3, 6, and 9 months after wide local excision. An Excellent-Good cosmetic result was scored more often than a Fair-Poor result for both treatment groups across all time points. The TARGIT-IORT patients reported better breast-related QOL than EBRT patients. Statistically and clinically significant differences were seen at month 6 and year 1, with EBRT patients having moderately worse breast symptoms (a statistically significant difference of more than 10 in a 100-point scale) than TARGIT-IORT patients at these time points. Patients treated with TARGIT-IORT on the TARGIT-A trial have similar self-reported cosmetic outcome but better breast-related QOL outcomes than patients treated with EBRT. This important evidence can facilitate the treatment decision-making process for patients who have early breast cancer suitable for breast-conserving surgery and inform their clinicians.
Publisher: IEEE
Publisher: IEEE
Date: 28-03-2022
No related grants have been discovered for Dharmapriya Bandara.